Forty-eight hirsute women were treated with spironolactone 100mg twice daily for 3 to 12 months.
Introduction
Hirsuties can be a distressing symptom in women and is often difficult to control, as reflected in the wide variety of drugs which have been used including corticosteroids, oral contraceptives and the antiandrogens cyproterone acetate and cimetidine, all of which are often relatively ineffective or have undesirable side effects'. The aldosterone antagonist spironolactone also has an antiandrogenic action, first seen during its use in the treatment ofhypertension as the unwanted side effects of gynaecomastia, loss of libido and impotence in men and menstrual irregularity in women2. In a hypertensive obese woman who was also hirsute, a marked improvement in the degree of hirsuties was seen following the treatment of her hypertension with spironolactone3. This suggested its use in the treatment ofhirsutism4'5.
In the present study we have assessed the results of treatment with spironolactone of women with idiopathic hirsutism (IH) and the polycystic ovary syndrome (PCOS).
Patients and methods
Forty-eight premenopausal women referred for the investigation and treatment ofhirsutism were treated with spironolactone 100 mg twice daily, after excluding endocrinopathies such as androgen-secreting tumours and Cushing's syndrome. Patient characteristics are shown in Table 1 . Twenty-four had evidence of PCOS (menstrual irregularity and increased luteinizing hormone (LH) (>8 u/1 other than at mid-cycle) with ultrasound evidence in 11 and a history of infertility in 9), while 24 had normal LH levels and were classed as IH. Twenty-two subjects had oligomenorrhoea (cycle length >35 days) and 4 had amenorrhoea of >3 months' duration. All patients were advised ofthe need for effective contraception because'of the possible effects of antiandrogen treatment in feminizing the male fetus1.
In those women using local treatments to control their hirsuties, the frequency of shaving, plucking, waxing or use of depilatory creams was recorded. In those not using such methods, facial hirsuties was graded on an arbitary scale of 1 to 5 based on the distribution and density of the hair growth over the face (upper lip, chin and sideburns) and body (arms, legs, chest, abdomen and back). Plasma testosterone was measured by radioimmunoassay.
The results of treatment were assessed at 3 months and, in 16 subjects, again at 12 months. The studies were carried out with the approval of the hospital ethical committe'e and informed consent of each subject. Results were analysed using Student's paired and unpaired t tests and linear regression analysis for normally distributed data (welght, age, plasma testosterone) and the Wilcoxon matched pairs signed ranks test, Mann-Whitney U test and Spearman rank correlation otherwise (hirsuties gradings and treatment frequency).
Results
Of 48 hirsute women treated with spironolactone, 42 reported moderate to marked improvement in their subjective assessment of the degree of hirsuties. Facial hirsuties improved by 1.2 +0.2 grades (mean-+ s.e.mean), a 39% reduction, while body hirsuties diminished by 0.9±0.1 grades, a 29% reduction, with all parts of the body being affected to a similar extent ( Table 2 ). The treatment frequency of the face and legs fell by 3.4 and 2.7 fold respectively. Plasma testosterone fell by 0.9±0.2nmol/1 (P<0.001), and body weight by 2.9 ±0.5 kg (P<0.001) at 3 months. The change in testosterone was not significantly correlated with the change in body weight (r= 0.01), or with the change in facial (rs= -0.18) or body (rs=-0.05) hirsuties, but was proportional to the initial plasma testosterone (r= 0.79, P<0.001). There was no further decrease in plasma testosterone or in body weight after 3 months. The improvement in both facial and body hirsuties, however, was slightly greater at 12 months than at 3 months (facial 1.4 ±0.4 versus 0.8 ±0.2 grades, P= NS; body 1.0+0.2 versus 0.7 +0.2 grades, P<0.05).
When subjects with PCOS were compared to those with IH, there were no significant differences in the degree of facial or body hirsuties or in age, weight or body mass index. Plasma testosterone, however, was significantly greater in the PCOS Three of the 22 women whose menses were initially regular developed polymenorrhoea, whilst menses were unaltered in the remainder. Of the 22 women initially oligomennorhoeic, 2 became amenorrhoeic, menses were unaltered in 6 and became regular in 10, while 4 developed polymenorrhoea or menorrhagia. Two of the 4 women who initially had amenorrhoea resumed menses, though remaining oligomenorrhoeic. No electrolyte imbalance occurred during treatment, and no other adverse effects apart from transient nausea and mild diuresis were reported. Ten patients (21%) (included in the analysis) discontinued treatment after 2-9 months, 6 because of lack of effect and 4 because of the adverse effect on menses.
Discussion
Spironolactone in the dosage used in the present study proved an effective treatment for hirsuties in the majority of patients, in both PCOS and IH. All regions of the body benefited to a similar extent. Previous studies of smaller numbers of patients4 -12 have yielded conflicting views as to its efficacy; this can probably be attributed to differences in the dose of spironolactone employed, those using 200 mg daily reporting similar responses to those in the present study and those using lower doses reporting lower success rates. Most of the improvement in hirsuties was already manifest at 3 months, though there was a further small improvement by 12 months. The effects may be delayed if a cyclical regimen of spironolactone administration is employed5. There. were few adverse effects other than polymenorrhoea, menorrhagia or oligo-amenorrhoea in 9 women, of sufficient severity to result in cessation of treatment in only 4. Menstrual regularity improved in 12 women whose periods were initially irregular. Mild polyuria was the only other reported side effect and, unlike its use in subjects with renal, cardiac or hepatic disease'3, there were no electrolyte disturbances.
The fall in weight accompanying spironolactone therapy was probably largely related to its diuretic action since no further weight reduction was seen after the first 3 months.
The comparable improvement in hirsuties in PCOS and IH despite the greater fall in plasma testosterone in PCOS, the lack of correlation between the fall in testosterone and improvement in hirsuties, and the continued improvement in hirsuties with no further fall in plasma testosterone with increasing duration of treatment, suggest that a peripheral action of spironolactone is as important as its action in reducing plasma testosterone levels. Spironolactone is known to bind to androgen receptors in the skin as well as other peripheral tis-sues2"14'15, inhibiting androgen action peripherally, as well as reducing the testosterone production rate in both hirsute and non-hirsute women4; this is presumably the result of its inhibition of cytochrome P450 oxidase and hence 17-hydroxylase action in both gonads and adrenals2"16.
Regardless of the mechanisms responsible, spironolactone proved an effective agent with few unwanted effects in the treatment of hirsutism in both PCOS and IH. Further studies are needed to determine whether a lower dose of spironolactone, which might result in fewer menstrual irregularities, may suffice to maintain the improvement in hirsuties obtained on the higher dose.
